418 related articles for article (PubMed ID: 30136337)
41. No distinction in the gut microbiota between diarrhea predominant-irritable bowel syndrome and healthy subjects: matched case-control study in Thailand.
Jandee S; Chuensakul S; Maneerat S
Gut Pathog; 2021 Mar; 13(1):16. PubMed ID: 33658063
[TBL] [Abstract][Full Text] [Related]
42. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life.
Choi CH; Jo SY; Park HJ; Chang SK; Byeon JS; Myung SJ
J Clin Gastroenterol; 2011 Sep; 45(8):679-83. PubMed ID: 21301358
[TBL] [Abstract][Full Text] [Related]
43. A Nonviable Probiotic in Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.
Mack I; Schwille-Kiuntke J; Mazurak N; Niesler B; Zimmermann K; Mönnikes H; Enck P
Clin Gastroenterol Hepatol; 2022 May; 20(5):1039-1047.e9. PubMed ID: 34214682
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial.
Bensoussan A; Kellow JE; Bourchier SJ; Fahey P; Shim L; Malcolm A; Boyce P
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1946-54.e1. PubMed ID: 26133902
[TBL] [Abstract][Full Text] [Related]
45. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
46. Combination of a Probiotic and an Antispasmodic Increases Quality of Life and Reduces Symptoms in Patients with Irritable Bowel Syndrome: A Pilot Study.
Barraza-Ortiz DA; Pérez-López N; Medina-López VM; Minero-Alfaro JI; Zamarripa-Dorsey F; Fernández-Martínez NDC; Llorente-Ramón A; Ramos-Aguilar GA
Dig Dis; 2021; 39(3):294-300. PubMed ID: 32810850
[TBL] [Abstract][Full Text] [Related]
47. Gut fungal dysbiosis and altered bacterial-fungal interaction in patients with diarrhea-predominant irritable bowel syndrome: An explorative study.
Hong G; Li Y; Yang M; Li G; Qian W; Xiong H; Bai T; Song J; Zhang L; Hou X
Neurogastroenterol Motil; 2020 Nov; 32(11):e13891. PubMed ID: 32449259
[TBL] [Abstract][Full Text] [Related]
48. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial.
Shin SY; Park S; Moon JM; Kim K; Kim JW; Chun J; Lee TH; Choi CH;
J Neurogastroenterol Motil; 2022 Oct; 28(4):642-654. PubMed ID: 36250371
[TBL] [Abstract][Full Text] [Related]
49. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes.
Lyra A; Krogius-Kurikka L; Nikkilä J; Malinen E; Kajander K; Kurikka K; Korpela R; Palva A
BMC Gastroenterol; 2010 Sep; 10():110. PubMed ID: 20849659
[TBL] [Abstract][Full Text] [Related]
50. Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome.
Moser AM; Spindelboeck W; Halwachs B; Strohmaier H; Kump P; Gorkiewicz G; Högenauer C
Eur J Nutr; 2019 Oct; 58(7):2767-2778. PubMed ID: 30251020
[TBL] [Abstract][Full Text] [Related]
51. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis.
Liu HN; Wu H; Chen YZ; Chen YJ; Shen XZ; Liu TT
Dig Liver Dis; 2017 Apr; 49(4):331-337. PubMed ID: 28179092
[TBL] [Abstract][Full Text] [Related]
52. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
Bafutto M; Almeida JR; Leite NV; Costa MB; Oliveira EC; Resende-Filho J
Arq Gastroenterol; 2013; 50(4):304-9. PubMed ID: 24474234
[TBL] [Abstract][Full Text] [Related]
53. Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probiotics.
Staudacher HM; Scholz M; Lomer MC; Ralph FS; Irving PM; Lindsay JO; Fava F; Tuohy K; Whelan K
Clin Nutr; 2021 Apr; 40(4):1861-1870. PubMed ID: 33183883
[TBL] [Abstract][Full Text] [Related]
54. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome.
Carroll IM; Ringel-Kulka T; Siddle JP; Ringel Y
Neurogastroenterol Motil; 2012 Jun; 24(6):521-30, e248. PubMed ID: 22339879
[TBL] [Abstract][Full Text] [Related]
55. A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome.
Roberts LM; McCahon D; Holder R; Wilson S; Hobbs FD
BMC Gastroenterol; 2013 Mar; 13():45. PubMed ID: 23496803
[TBL] [Abstract][Full Text] [Related]
56. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
Fukudo S; Ida M; Akiho H; Nakashima Y; Matsueda K
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):953-9.e4. PubMed ID: 24315882
[TBL] [Abstract][Full Text] [Related]
57. Intestinal Microbiome in Irritable Bowel Syndrome before and after Gut-Directed Hypnotherapy.
Peter J; Fournier C; Keip B; Rittershaus N; Stephanou-Rieser N; Durdevic M; Dejaco C; Michalski M; Moser G
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30453528
[TBL] [Abstract][Full Text] [Related]
58. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome.
Halmos EP; Power VA; Shepherd SJ; Gibson PR; Muir JG
Gastroenterology; 2014 Jan; 146(1):67-75.e5. PubMed ID: 24076059
[TBL] [Abstract][Full Text] [Related]
59. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome.
Duboc H; Rainteau D; Rajca S; Humbert L; Farabos D; Maubert M; Grondin V; Jouet P; Bouhassira D; Seksik P; Sokol H; Coffin B; Sabaté JM
Neurogastroenterol Motil; 2012 Jun; 24(6):513-20, e246-7. PubMed ID: 22356587
[TBL] [Abstract][Full Text] [Related]
60. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification.
Engsbro AL; Simren M; Bytzer P
Aliment Pharmacol Ther; 2012 Feb; 35(3):350-9. PubMed ID: 22176384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
